Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase 1 | terminated | Oct 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT05388851 | Education for Prevention of Melanoma in Hispanic Populations | Phase 2 | terminated | May 24, 2022 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | Phase 1 / Phase 2 | terminated | Oct 30, 2017 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04698187 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | Phase 2 | terminated | Jan 6, 2021 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With…(ARTISTRY-6) | Phase 2 | terminated | Apr 2, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | — | withdrawn | Sep 23, 2019 | ProgenaBiome | Sponsor decision | Sponsor / business decision |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable… | Phase 1 | withdrawn | Jan 5, 2024 | James Isaacs, MD | Iovance withdrew support due to length of time required to meet accrual goal. | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | Phase 2 | withdrawn | Sep 26, 2007 | Biogen | not stated | Not stated |
| NCT01864538 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | Phase 2 | terminated | May 29, 2013 | ImmunoGenesis | Lack of enrollment | Enrollment / accrual |
| NCT00716560 | Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin | — | terminated | Jul 16, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Administratively terminated. | Other (stated, no rule matched) |
| NCT02145910 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With… | Phase 1 | withdrawn | May 23, 2014 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Study was never opened to accrual. There is no clinical benefit to patients. | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Phase 1 | terminated | Nov 28, 2016 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04625205 | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy… | Phase 1 | terminated | Nov 12, 2020 | BioNTech US Inc. | Sponsor decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal… | Phase 2 | terminated | Jun 29, 2022 | Yonsei University | According to the protocol criteria, during the Phase 1 analysis, the registered participants'… | Other (stated, no rule matched) |
| NCT05695898 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune… | Phase 1 | terminated | Jan 25, 2023 | University of California, San Francisco | Sponsor decision | Sponsor / business decision |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | Phase 1 | terminated | Aug 4, 2021 | Nouscom SRL | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03997474 | ATL001 in Patients With Metastatic or Recurrent Melanoma | Phase 1 / Phase 2 | terminated | Jun 25, 2019 | Achilles Therapeutics UK Limited | Sponsor decision | Sponsor / business decision |
| NCT04901988 | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION(DETECTION) | Phase 2 / Phase 3 | terminated | May 26, 2021 | The Christie NHS Foundation Trust | Closed earlier than expected due to the need for a redesign to reflect the recent change in… | Other (stated, no rule matched) |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma… | Phase 1 / Phase 2 | withdrawn | May 25, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT00560118 | Fotemustine in Treating Patients With Metastatic Melanoma(MGFOT1) | Phase 2 | terminated | Nov 19, 2007 | Institut du Cancer de Montpellier - Val d'Aurelle | In view of the slowness of the inclusions and the difficulty of carrying out the study, it was… | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or… | Phase 1 | withdrawn | Dec 16, 2022 | Mayo Clinic | Sponsor business considerations | Sponsor / business decision |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04967196 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic… | Phase 1 | terminated | Jul 19, 2021 | Mayo Clinic | Lack of funding | Funding |
| NCT03950635 | Dietary Intervention in Patients with a History of Melanoma | Phase 1 | terminated | May 15, 2019 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or… | Phase 2 | terminated | May 5, 2020 | Jonsson Comprehensive Cancer Center | poor enrollment | Enrollment / accrual |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | Phase 2 | terminated | Feb 24, 2023 | ImaginAb, Inc. | Strategic decision | Sponsor / business decision |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer… | Phase 2 | terminated | Jul 14, 2022 | Astellas Pharma Inc | Company's strategic decision | Sponsor / business decision |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating… | Phase 1 / Phase 2 | terminated | Oct 8, 2010 | National Cancer Institute (NCI) | Other - Protocol moved to Administratively Complete | Other (stated, no rule matched) |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When…(LTbR) | Phase 1 | terminated | Jun 7, 2024 | Pfizer | Strategic business decision | Sponsor / business decision |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or… | Phase 1 | terminated | Mar 27, 2014 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and… | Phase 2 | terminated | Mar 18, 2009 | Wake Forest University Health Sciences | administrative decision- PI retired and treating physician left the institution | Other (stated, no rule matched) |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | Phase 2 | terminated | Mar 23, 2018 | Ralph Hauke | Lack of Accrual | Enrollment / accrual |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial… | Phase 2 | withdrawn | Feb 28, 2018 | European Institute of Oncology | no financial support | Funding |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune…(SPICE) | — | withdrawn | Jun 18, 2019 | University of Cologne | Administrative reasons | Other (stated, no rule matched) |
| NCT03712358 | PVSRIPO for Patients With Unresectable Melanoma | Phase 1 | terminated | Oct 19, 2018 | Istari Oncology, Inc. | Study closed to enrollment due to business decision prior to enrolling Cohort 4 | Enrollment / accrual |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Phase 2 | terminated | Jan 20, 2022 | Providence Health & Services | Withdrawn support from BMS. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 1, 2025source: clinicaltrials